HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

H Serve Selected Research

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)

7/2020Correction: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.
1/2019Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.
1/2017Plastic CD34 and CD38 expression in adult B-cell precursor acute lymphoblastic leukemia explains ambiguity of leukemia-initiating stem cell populations.
6/2013Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia.
7/2012Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


H Serve Research Topics

Disease

18Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2018 - 12/2000
12Neoplasms (Cancer)
03/2013 - 04/2000
6Leukemia
01/2017 - 09/2003
5Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
07/2020 - 07/2012
3Residual Neoplasm
07/2020 - 06/2013
2Acute Promyelocytic Leukemia
12/2009 - 12/2000
2Stomach Neoplasms (Stomach Cancer)
09/2006 - 06/2006
2Hematologic Neoplasms (Hematological Malignancy)
09/2003 - 07/2002
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
10/2001 - 01/2001
1Pathologic Complete Response
01/2018
1Splenomegaly
03/2016
1Hemorrhage
03/2016
1Myelodysplastic Syndromes (Myelodysplastic Syndrome)
01/2016
1Infections
08/2013
1Philadelphia Chromosome
07/2012
1Cardiotoxicity
04/2012
1Adenocarcinoma
09/2006
1Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/2002
1Neoplasm Metastasis (Metastasis)
01/2001
1Myeloid Leukemia (Leukemia, Myelocytic)
12/2000
1Glioblastoma (Glioblastoma Multiforme)
09/2000
1Glioma (Gliomas)
09/2000
1Osteosarcoma (Osteogenic Sarcoma)
05/2000
1Multiple Myeloma
04/2000

Drug/Important Bio-Agent (IBA)

4Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
09/2006 - 12/2000
4Cyclin A1IBA
04/2001 - 05/2000
3Cytarabine (Cytosar-U)FDA LinkGeneric
01/2018 - 12/2009
3Imatinib Mesylate (Gleevec)FDA Link
06/2013 - 06/2006
3Phosphotransferases (Kinase)IBA
07/2012 - 06/2006
3Proteins (Proteins, Gene)FDA Link
01/2004 - 12/2000
2RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
07/2020 - 01/2019
2tyrosine receptor (receptor, tyrosine)IBA
08/2007 - 06/2006
2ErbB Receptors (EGF Receptor)IBA
09/2006 - 06/2006
2Gefitinib (Iressa)FDA Link
09/2006 - 06/2006
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
07/2002 - 04/2000
2CyclinsIBA
01/2001 - 12/2000
1Amsacrine (AMSA)IBA
01/2018
1Mitoxantrone (Novantrone)FDA LinkGeneric
01/2018
1Daunorubicin (Cerubidine)FDA LinkGeneric
01/2018
1PlasticsIBA
01/2017
1DNA Methyltransferase 3AIBA
01/2017
1Heparin (Liquaemin)FDA LinkGeneric
03/2016
1Azacitidine (5 Azacytidine)FDA Link
03/2016
1fms-Like Tyrosine Kinase 3IBA
02/2016
1fludarabineIBA
05/2014
1quizartinibIBA
03/2014
1Ribavirin (Virazole)FDA LinkGeneric
08/2013
1Gemtuzumab (Mylotarg)FDA Link
04/2012
1Tretinoin (Retinoic Acid)FDA LinkGeneric
12/2009
1AnthracyclinesIBA
03/2008
1Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA
01/2008
1Transcription Factors (Transcription Factor)IBA
08/2007
1Retinoic Acid Receptor alphaIBA
08/2007
1Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
09/2006
1Bevacizumab (Avastin)FDA Link
06/2006
1Erlotinib Hydrochloride (CP 358,774)FDA Link
06/2006
1Trastuzumab (Herceptin)FDA Link
06/2006
1Cetuximab (Erbitux)FDA Link
06/2006
1Tumor Suppressor Protein p14ARF (p14ARF)IBA
04/2004
1Messenger RNA (mRNA)IBA
04/2004
1Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA
09/2003
1Constitutive Androstane ReceptorIBA
09/2003
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
09/2003
1Growth Factor ReceptorsIBA
10/2002
1Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
07/2002
1IfosfamideFDA LinkGeneric
01/2002
1Etoposide (VP 16)FDA LinkGeneric
01/2002
1Carboplatin (JM8)FDA LinkGeneric
01/2002
1Cyclin AIBA
01/2001
1Cyclin-Dependent Kinases (cdk Proteins)IBA
01/2001
1Cyclin EIBA
01/2001
1Cyclin A2IBA
01/2001
1Oncostatin MIBA
09/2000
1Mitogen-Activated Protein KinasesIBA
09/2000
1Glial Fibrillary Acidic ProteinIBA
09/2000
1enhanced green fluorescent proteinIBA
05/2000
1Interleukin-6 (Interleukin 6)IBA
04/2000
1CytokinesIBA
04/2000

Therapy/Procedure

6Therapeutics
01/2016 - 01/2002
3Induction Chemotherapy
03/2016 - 12/2009
3Drug Therapy (Chemotherapy)
01/2016 - 03/2008
2Cell Transplantation
11/2017 - 05/2015
1Hematopoietic Stem Cell Transplantation
05/2015
1Stem Cell Transplantation
06/2013
1Complementary Therapies (Alternative Medicine)
03/2013